Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS)

Historical Holders from Q4 2015 to Q3 2025

Symbol
ACRS on Nasdaq
Type / Class
Equity / Common Stock, par value $0.00001 per share
Shares outstanding
108M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
85.7M
Holdings value
$163M
% of all portfolios
0.001%
Grand Portfolio weight change
0%
Number of holders
103
Number of buys
40
Number of sells
-47
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BML Investment Partners, L.P. 13.3% $21.8M 14.3M BML Investment Partners, L.P. 31 Dec 2024
VANGUARD GROUP INC 6.15% +31% $9.46M $2.4M 6.66M +34% The Vanguard Group 30 Jun 2025
BlackRock, Inc. 5.1% $7.77M 5.47M BlackRock, Inc. 30 Jun 2025
Adage Capital Management, L.P. 4.87% -34.1% $10M -$5.55M 5.28M -35.6% Adage Capital Management, L.P. 30 Sep 2025
Rock Springs Capital Management LP 4.7% $7.72M 5.05M Rock Springs Capital Management LP 31 Mar 2025
MILLENNIUM MANAGEMENT LLC 3.5% -32% $5.45M -$2.42M 3.84M -30.8% Millennium Management LLC 30 Jun 2025

Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 85.7M $163M -$11.3M $1.90 103
2025 Q2 91.9M $130M -$2.09M $1.42 95
2025 Q1 92.2M $141M +$2.11M $1.53 106
2024 Q4 87.5M $217M +$93.7M $2.48 97
2024 Q3 50.9M $58.5M -$1.74M $1.15 76
2024 Q2 52.8M $58.1M -$1.62M $1.10 93
2024 Q1 54.4M $67.4M -$3.79M $1.24 93
2023 Q4 58.4M $61.4M -$207M $1.05 102
2023 Q3 70.1M $480M -$28.1M $6.85 137
2023 Q2 71M $736M +$5.84M $10.37 131
2023 Q1 71.6M $579M +$19.6M $8.09 148
2022 Q4 65.9M $1.04B -$2.54M $15.75 126
2022 Q3 63.7M $1B +$5.53M $15.74 124
2022 Q2 63.3M $883M +$55.2M $13.96 112
2022 Q1 59.3M $1.02B +$59.4M $17.24 107
2021 Q4 56M $815M -$39.8M $14.54 133
2021 Q3 56.8M $1.02B +$15.3M $18.00 126
2021 Q2 56M $983M +$20.6M $17.56 128
2021 Q1 45.4M $1.3B +$509M $25.20 95
2020 Q4 31.9M $207M +$27.7M $6.47 79
2020 Q3 25.6M $65.7M -$3.89M $2.57 52
2020 Q2 28.5M $46.1M -$5.51M $1.62 56
2020 Q1 32.1M $33.4M +$3.16M $1.04 65
2019 Q4 30.8M $58.2M +$3.33M $1.89 72
2019 Q3 29.1M $31.4M -$19.2M $1.08 76
2019 Q2 35.6M $78M -$16.3M $2.19 82
2019 Q1 37.9M $227M -$11.1M $5.99 91
2018 Q4 39.1M $289M +$36.6M $7.39 95
2018 Q3 29.7M $431M -$29.5M $14.52 81
2018 Q2 31M $619M +$11.7M $19.97 92
2018 Q1 30.6M $536M +$33.8M $17.52 100
2017 Q4 28.5M $703M -$10.6M $24.66 102
2017 Q3 28.5M $697M +$73.6M $25.81 102
2017 Q2 25.6M $694M +$43.7M $27.12 101
2017 Q1 23.7M $707M +$74.7M $29.82 111
2016 Q4 21.4M $579M +$95.8M $27.14 100
2016 Q3 15.5M $397M +$4.35M $25.61 59
2016 Q2 15.4M $284M +$13.3M $18.47 47
2016 Q1 14.6M $277M +$2.04M $18.95 34
2015 Q4 10.3M $277M +$277M $26.94 33